MNOV Stock — Medicinova Inc: Cash, EV, Pipeline

Share price

$3.32

Market cap

$163.4M

Cash

$25.4M

Enterprise value

$138.0M

Balance sheet

Cash	$25.4M
Debt	$0.0M
Net cash	$25.4M
Enterprise value	$138.0M
Basic shares	49.2M shares
Fully diluted shares	57.5M shares
Fully diluted market cap	$191.0M
Cash per share	$0.52

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MNOV daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	MN-001	Phase 2	Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease	—
May 13 - Jun 24	MN-166	Phase 2/3	Amyotrophic Lateral Sclerosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MN-166

Stage not disclosed · Active

Aliases ibudilast

Target MIF/PDE

Partnerships Mayo Foundation for Medical Education and Research (clinical research services agreement to evaluate MN-166 in ALS)

Indications

Progressive multiple sclerosis (MS) (Stage not disclosed)
Amyotrophic lateral sclerosis (ALS) (Stage not disclosed)
Chemotherapy-induced peripheral neuropathy (Stage not disclosed)
Degenerative cervical myelopathy (DCM) (Stage not disclosed)
Glioblastoma (Stage not disclosed)
Prevention of acute respiratory distress syndrome (ARDS) (Stage not disclosed)

Status note Advanced through investigator-sponsored, government/grant-funded, and company-funded trials. Mayo Foundation clinical research services agreement (December 2024, extended to August 2026) to evaluate MN-166 in ALS; first study site enrolled patients in March 2025.

MN-001

Stage not disclosed · Active

Aliases tipelukast

Target LT receptor / PDE3/4 / 5-LO

Indications

Fibrotic disorders (e.g., nonalcoholic fatty liver disease/NAFLD) (Stage not disclosed)
Metabolic disorders (e.g., hypertriglyceridemia) (Stage not disclosed)

Status note Second named product candidate; company intends to advance development through investigator-sponsored or grant-funded trials as well as company-funded trials.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	MN-166
Lead indication	Amyotrophic Lateral Sclerosis
Lead phase	Phase 2/3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04057898	Phase 2/3	Active, not recruiting	Sponsor	MediciNova	—	Amyotrophic Lateral Sclerosis	—
NCT05464784	Phase 2	Active, not recruiting	Sponsor	MediciNova	—	Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for MediciNova on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

MNOV — Medicinova Inc